CAPLYTA® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials

Among the secondary endpoints for the adjunctive MDD therapies evaluated, CAPLYTA® demonstrated no weight gain compared to placebo plus antidepressant therapy

Featured in a late-breaking presentation at the 2026 NEI Spring Congress, analysis provides indirect comparisons to help inform treatment decisions in the absence of head-to-head clinical trials